Aptorum Group Extends DiamiR Merger Agreement Termination Date to July 31, 2026
APM sits 32% above its 52-week low of $0.65.
Summary
Aptorum Group has again extended the termination date for its reverse merger agreement with DiamiR Biosciences to July 31, 2026, following shareholder approval earlier this month.
Key Events · M&A and Partnerships · APM
-
Merger Agreement Extension
Aptorum Group and DiamiR Biosciences Corp. extended the termination date for their merger agreement and related management services and licensing agreements to July 31, 2026.
-
Previous Extensions
This marks the third amendment to the management services agreement, with prior extensions to December 31, 2025, March 10, 2026, and June 30, 2026.
-
Shareholder Approval
The extension follows shareholder approval of the merger on June 10, 2026, indicating ongoing efforts to satisfy closing conditions.
Analysis · APM · Industrial Applications And Services
This extension is a procedural step to finalize the critical reverse merger with DiamiR Biosciences, which shareholders approved earlier this month. While the repeated extensions suggest administrative complexities in meeting closing conditions, the recent shareholder approval and a new collaboration announcement with DiamiR indicate the merger is still progressing. For a micro-cap company facing a going concern warning, successfully closing this merger is vital for its future operations.
At the time of this filing, APM was trading at $0.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7M. The 52-week trading range was $0.65 to $4.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.